AnaptysBio Inc. (ANAB)
NASDAQ: ANAB
· Real-Time Price · USD
20.11
0.14 (0.70%)
At close: Aug 15, 2025, 3:59 PM
20.14
0.12%
After-hours: Aug 15, 2025, 04:54 PM EDT
0.70% (1D)
| Bid | 19.1 |
| Market Cap | 563.16M |
| Revenue (ttm) | 123.16M |
| Net Income (ttm) | -132.59M |
| EPS (ttm) | -4.39 |
| PE Ratio (ttm) | -4.58 |
| Forward PE | -4.44 |
| Analyst | Buy |
| Ask | 20.66 |
| Volume | 275,721 |
| Avg. Volume (20D) | 589,291 |
| Open | 20.00 |
| Previous Close | 19.97 |
| Day's Range | 19.63 - 20.22 |
| 52-Week Range | 12.21 - 40.70 |
| Beta | -0.19 |
About ANAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
AnaptysBio has released their quartely earnings
on Aug 6, 2025:
Next Earnings Release
AnaptysBio Inc. is scheduled to release its earnings on
Nov 4, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+7.59%
AnaptysBio shares are trading higher after the com...
Unlock content with
Pro Subscription
4 months ago
+9.54%
AnaptysBio shares are trading higher after the company announced a $75 million share buyback program.
1 week ago · fool.com
AnaptysBio (ANAB) Q2 Revenue Jumps 103%AnaptysBio (ANAB) Q2 Revenue Jumps 103%
2 months ago · seekingalpha.com
AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster PotentialRosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant ...
2 months ago · seekingalpha.com
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab AdvancementAnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also b...
